Background: Percutaneous left ventricular transapical access (TA) can be utilized for a multitude of diagnostic and interventional procedures in structural heart disease (SHD) . With advancements in imaging and device technology, applicability of this approach is expanding. We present our growing experience in utilizing TA for structural heart interventions. Methods: We evaluated patients at our center, from April 2008 to June 2013, who presented for SHD intervention. Ninety four TA were performed in 80 consecutive patients (54 males, 71AE30 years) with 4 patients having double TA during the same intervention and 10 patients having repeat TA during subsequent SHD interventions (double TA n¼13). Since August 2010, computed tomographic angiography (CTA)/ fluoroscopy fusion imaging (HeartNavigator, Philips, Netherlands) has been used to guide TA puncture. Results: All TA were successfully performed for the following interventions: 74 mitral paravalvular leak (PVL) closure, 6 aortic PVL closure, 14 left ventricular pseudoaneurysm (LVPA) closure, 2 ventricular septal defect closure, 8 mitral transcatheter valve-in-valve implantations, and 10 combined procedures. Average initial/ final sheath sizes were 6F and 7F (range 5F-12F). TA was closed using an Amplatzer Ductal Occluder n¼86, Amplatzer Vascular Plug II n¼3, Muscular VSD Occluder n¼3, and coils n¼2. Complications occurred in 13 cases (14%): hemothorax n¼5, pericardial effusion/tamponade n¼1; persistent access site bleeding requiring surgical closure n¼2, non-fatal device migration n¼3 (2 ventricular, 1 epicardial requiring surgical closure), and death n¼2. One death occurred in a patient with suprasystemic pulmonary hypertension developing pulseless electrical activity and one death occurred after PVL closure in the setting of untreated critical aortic stenosis and epicardial device migration. There was no significant difference in complications associated with use of fusion imaging (with 10% vs without 17.6%, p¼0.29). Conclusions: TA is useful in multiple SHD interventions. Despite fusion imaging, complications still occur. More reliable TA closure devices may further improve the safety and generalizabilty of this approach for more complex SHD interventions.
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Long-term recurrent ischemic event rates after percutaneous closure of patent foramen ovale in patients with paradoxical embolism Marius Hornung 1 , Jennifer Franke 1 , Stefan C. Bertog 1 , Dani Id 1 , Ilona Hofmann 1 , Laura Vaskelyte 1 , Horst Sievert 1 1 CardioVascular Center Frankfurt, Frankfurt, Germany Background: Patients with a patent foramen ovale (PFO) and a history of paradoxical embolism are at risk to suffer from recurrent events even if the PFO was closed percutaneously. This study investigated the long-term results of a high-volume center. Methods: PFOs were closed in patients with a history of at least one assumed paradoxical embolism (TIA, stroke or peripheral embolism) or a diving accident. The type of closure device was chosen due to availability and operator's decision. All patients were prescribed a dual antiplatelet therapy (aspirin and clopidogrel) for the first 6 months after the procedure. Echocardiographic studies were performed at 4 weeks and 6 months after the index procedure. Patients were evaluated for residual shunts and the incidence of potential adverse events. All patients were followed annually through office visits, questionnaires and phone calls, or by contacting the referring physicians. Results: Between August 1998 and December 2012 percutaneous closure of patent foramen ovale was performed in 2831 patients. The mean age of patients was 50 AE 13 years. 55% were male (n¼1551). Indication for PFO-closure was a history of migraine (n¼481), peripheral embolism (n¼55), diving accident (n¼36) or cryptogenic cerebral ischemia (TIA in n¼1334 or stroke in n¼1666). 563 patients (19.9%) suffered from recurrent neurological events before percutaneous PFO-closure. We used 23 different types of closure devices. The most commonly used occluders were the Amplatzer (n¼914), the Helex (n¼470), the Premere (n¼409) and the CardioSEAL-STARflex device (n¼303). Within a total of 8,873 patient years of follow-up (mean follow-up duration: 38 months), there were 89 recurrent embolic events. This compares to an annual event rate of 1.0%. 29 patients suffered from recurrent TIA, and in 54 patients an ischemic strokes occurred. In 6 patients peripheral embolic events occurred. In 122 patients (4.3%) a second device implantation was performed to close a residual shunt.
Conclusions:
The results of this study represent the clinical experience of a European high-volume center in PFO-closure and show a favorable and much lower annual recurrent event rate compared to previously published randomized trials.
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Effect Background: We assessed the predictors of length of hospital stay (LOS) and cost of care related to percutaneous closure of ASD and PFO closure. Methods: We examined the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample (NIS) database from 2001 to 2010 using ICD 9-CM code for percutaneous ASD/PFO closure (35.52). Only adult (age > 18 year) patients with ASD/PFO (ICD 9-CM -745.5) were included in study. We could not differentiate between ASD and PFO closure due to the same ICD9 code for both procedures. NIS is represents 20% of all US hospitals. Cost to charge ratio files were merged with NIS to calculate cost of care. Cost was adjusted for inflation in reference to 2010. Comorbid conditions were defined by Charlson's Comorbidity Index (CCI). Hierarchical multilevel regression models were generated to determine independent predictors of LOS and cost of care. Results: Total of 7,107 (weighted n¼34,990) percutaneous ASD/PFO closure procedures were analyzed. Average LOS and cost of care for percutaneous ASD/PFO closure were 2.63AE0.06 days and $16,635AE225, respectively. LOS was increased (days, 95% CI, P-value) with presence of any complication (+2.47 days, 2.14-2.80, P 2 (+1.84 days, 1.48-2.20, P<0.001). Decrease in LOS was associated with use of higher operator volume tertile(-2.58 days, -3.04 --2.12, P2) (1.17, 1.12-1.22, P<0.001). Decrease in cost was associated with higher annual operator volume tertile (0.84, 0.08 -0.88, P<0.001).
B32
JACC Vol Diego class I:0, II:3, III:15, IV:7) . BPA was repeated in 1 to 6 sessions to every patient depending on their severity. We evaluated hemodynamics by Swan-Ganz catheter at baseline and post procedure. Results: PEA significantly improved hemodynamics in operable patients (Table) . In non-operable patients, even BPA dramatically improved hemodynamic parameters such as a significant increase in cardiac output (CO) and decrease in mPAP and pulmonary vascular resistance (PVR), which were accompanied with improved 6minute walk distance (6MWD) and WHO-Fc as observed in PEA for operable patients. Reperfusion pulmonary injury occurred in 3 patients (14.3%) after PEA, and in 21 sessions (32.8%) after BPA with 3 sessions required emergent intubation. Two patients (9.5%) died after PEA due to persistent of right heart failure and 1 patient (4.0%) died after BPA due to systemic infection.
Conclusions: BPA could be an effective treatment option for non-operable CTEPH to achieve dramatic improvement of hemodynamic and outcome parameters. The efficacy and safety for non-operable cases were equivalent to those of PEA for operable cases.
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Is fetal aortic valvuloplasty effective to achieve a biventricular circulation after birth?
Carlos Pedra 1 , Simone Pedra 2 , Rodrigo Costa 2 , Marcelo Ribeiro 2 , Fabio Peralta 2 1 Hospital do Coração, São Paulo, Brazil, 2 Hospital do Coração, Sao Paulo, Brazil
Background: Critical aortic stenosis (AS) in utero is a severe disease that may evolve to hypoplastic left heart syndrome (HLHS) if not treated. Fetal aortic valvuloplasty (AV) has been performed in selected cases to avert this progression. However, more data is required to assess its impact on achieving a biventricular circulation (BVC), especially in patients with smaller left ventricles (LV). We report the immediate procedural results and the postnatal outcomes up to one year of age of fetuses who underwent AV. Methods: Procedures were performed under spinal maternal block and fetal anesthesia between 23 to 34 weeks gestation through a transabdominal (maternal) and transthoracic (fetus) approach under echo guidance. The LV apex was entered using 17/18 G Chiba needles and the valve was dilated with coronary angioplasty balloons (1-1.2 times the valve annulus). Serial echos were performed pre and post natally.
Results: Thirteen fetuses underwent the procedure. Five were severely hydropic, 4 had severe mitral regurgitation and gigantic left atrium (GLA), 3 had hypoplastic LVs (2 severe). Endocardial fibroelastosis was present in all (severe in 6). In all but 1 fetus the valve was successfully crossed and dilated. Satisfactory antegrade flow was observed in 12 cases, aortic insufficiency in 7 and pericardial effusion AE bradycardia in 9 fetuses requiring needle aspiration + atropine. There were no maternal complications. There were 2 early neonatal deaths after premature delivery because of severe hydrops (both with GLA). BVC was achieved in 3 neonates. All required aortic valvuloplasty. Three with smaller LV underwent aortic valvuloplasty + hybrid procedures, with 2 undergoing LV overhaul and a BVC @ 9 months of age. In the other a BVC is still contemplated. One neonate born at another institution died on the first day of life, 3 were managed as univentricular hearts and 1 had comfort care (no LV growth).
Conclusions: Fetal aortic valvuloplasty may improve overall neonatal and infancy outcomes. BVC was achieved in 30% of the cases with a chance of improving to a 50% rate. Neonatal outcomes seem to depend on the clinical and anatomical fetal presentation, with hydropic fetuses having worse outcomes. 
